Crossmark

Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy

Crossref DOI link: https://doi.org/10.1007/s00280-024-04643-x

Published Online: 2024-03-02

Published Print: 2024-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ji, Yan https://orcid.org/0000-0001-9569-0574
Sy, Sherwin K. B. https://orcid.org/0000-0001-6405-9130
License Information

Text and Data Mining valid from 2024-03-02

Version of Record valid from 2024-03-02
More Information

Article History

Received: 25 September 2023

Accepted: 23 January 2024

First Online: 2 March 2024

Declarations

:

: Yan Ji and Sherwin Sy are employees and stockholders of Novartis Pharmaceuticals Corporation.